casirivimab: Clinical Trials

2 completed, 2 terminated. 4 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	4	Completed 2, Terminated 2
Phase 2	1	Completed 1

Follow casirivimab: new trials by email Literature Review of casirivimab trials Research Report on casirivimab

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults casirivimab+imdevimab, Placebo - Immunocompromised	Phase 3	Terminated	Regeneron Pharmaceuticals	66	2021-10-25	2025-10-20
ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19	Phase 2 / Phase 3	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	4044	2020-08-19	2024-08-02
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay REGN10933 + REGN10987, Placebo - Healthy Participants	Phase 3	Completed	Regeneron Pharmaceuticals	3303	2020-07-13	2023-05-15
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 casirivimab+imdevimab combination therapy - COVID-19	Phase 3	Terminated	Regeneron Pharmaceuticals	10078	2020-06-16	2023-12-21

Conditions studied

COVID-19 (3)  ·  Coronavirus Infections (2)  ·  Coronaviridae Infections (1)  ·  Nidovirales Infections (1)  ·  RNA Virus Infections (1)  ·  Severe Acute Respiratory Syndrome (1)  ·  Virus Diseases (1)

Sponsors

Regeneron Pharmaceuticals (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

United States (4)  ·  Mexico (3)  ·  Romania (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Canada (1)  ·  Guatemala (1)  ·  Moldova (1)  ·  Philippines (1)  ·  Puerto Rico (1)  ·  South Africa (1)

Top investigators

David Smith, MD, MAS (1)

Results publications

PMID 34473343, PMID 35713300, PMID 33332778, PMID 34159343, PMID 34159344, PMID 34347950, PMID 34587383, PMID 34981077, PMID 35029629, PMID 35793677, PMID 35797235, PMID 35803290, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37079569, PMID 37099295, PMID 37279602, PMID 37330602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 38102791, PMID 38961047, PMID 39018444, PMID 39028902, PMID 39384241, PMID 42148571